Evolus, Inc. (EOLS)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug

Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes

BlackRock Inc. Makes New Investment in Evolus, Inc. $EOLS

A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture

Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet

Evolus (NASDAQ:EOLS) Reaches New 52-Week High – Time to Buy?

Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS

Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade

Evolus: The Injectable Platform Is Becoming The Real Moat

Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript

Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2

Evolus Q2 Earnings Call Highlights

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook

Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand

Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand

Evolus to Report Second Quarter Financial Results on August 5, 2026

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)